How a molecule becomes a medicine

From lab hit to pharmacy shelf: the trial phases, the failure rates, and the patent clock that makes the whole industry run the way it does.

The question

A promising molecule is found in a lab. Years later it is at a pharmacy. What happens in between — and why does it cost so much and fail so often?

What's happening

The pipeline is not one process but a funnel, and the thing that shapes the entire industry is not the discovery; it is the attrition.

How it actually works

The path from molecule to medicine is a staged filter, where each stage is larger, longer and more expensive than the last:

Stage Purpose The brutal part
Discovery find a "hit" that binds the target thousands of candidates, mostly dead
Preclinical test in cells/animals for safety toxicity kills many here
Phase I safety in ~tens of healthy people dosing, side effects
Phase II does it work in patients? most failures happen here
Phase III large trials, vs. standard care the expensive, decisive stage
Approval regulator reviews the evidence years of review
Market manufacture, price, distribute the patent clock is already running

Three mechanisms explain the industry's behavior:

  1. Attrition drives cost. Because only a tiny fraction of candidates survive, the cost of the winners must carry the cost of the thousands of losers. This is why a single approved drug can cost billions to develop.
  2. Phase II is the graveyard. A molecule that is safe is not necessarily effective, and proving efficacy in real patients is where most programs die.
  3. The patent clock is the whole business model. A patent is filed early, but the drug only earns after approval — so the effective period of exclusivity is short. The industry runs on racing to approval, then maximizing revenue in the remaining window before generics arrive.

Everything about pharma strategy — the urgency, the pricing, the mergers — follows from two facts: most molecules fail, and successful ones have a countdown.

What's unknown

  • Whether AI-driven discovery meaningfully raises the survival rate, or mostly speeds up the earliest stage while leaving the Phase II graveyard intact.
  • How pricing is justified against R&D cost in a way that stays stable across countries.
  • Open: the exact shape of attrition by therapeutic area. Failure rates are wildly different for, say, oncology versus a new painkiller, and I only have rough figures.

Reading

  • Clinical-trial phase methodology and success-rate studies.
  • Pharmaceutical patent-term and exclusivity explanations.